IMM 01

Drug Profile

IMM 01

Alternative Names: IMM-01

Latest Information Update: 04 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunova
  • Developer Modulate Therapeutics
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Immunostimulants; Interleukin-2 receptor agonists; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Feb 2016 Eli Lilly has the option to acquire IMM-01 after completion of proof-of-concept studies
  • 01 Feb 2016 Preclinical trials in Cancer in Canada (Intratumoural) before February 2016
  • 01 Feb 2016 Immunova in-licenses nanoparticle delivery technology from Yale and John Hopkins University
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top